Biontech Se (BNTX) SEC Filings — 2024
36 SEC filings for Biontech Se (BNTX) in 2024.
Filings
- BioNTech SE Files 6-K, Discusses NIH Talks — 6-K · Dec 27, 2024
- BioNTech Partner's Drug IND Application Placed on Clinical Hold — 6-K · Dec 13, 2024
- BioNTech Hosts Innovation Series Day — 6-K · Nov 14, 2024
- Biontech Se SC 13G/A Filing — SC 13G/A · Nov 13, 2024
- BioNTech to Acquire Clinical-Stage Biopharma Biotheus — 6-K · Nov 13, 2024
- BioNTech SE Reports Q3 2024 Financial Results — 6-K · Nov 4, 2024
- BioNTech Partner's Drug Candidate Faces FDA Clinical Hold — 6-K · Oct 18, 2024
- BioNTech Showcases AI Progress at AI Day — 6-K · Oct 1, 2024
- BioNTech/Pfizer COVID Vaccine Gets EU Panel Recommendation — 6-K · Sep 20, 2024
- BioNTech to Present Oncology Data at ESMO 2024 — 6-K · Sep 5, 2024
- BioNTech/Pfizer COVID Vaccine Gets FDA Approval for Younger Ages — 6-K · Aug 22, 2024
- BioNTech Cancer Drug Trial Cleared by FDA — 6-K · Aug 19, 2024
- BioNTech & Pfizer Announce Phase 3 Vaccine Trial Results — 6-K · Aug 16, 2024
- BioNTech SE Updates on Penn Discussions — 6-K · Aug 7, 2024
- BioNTech SE Reports Q2 2024 Financial Results — 6-K · Aug 5, 2024
- BioNTech SE Announces Positive Phase 2 Data for Influenza Vaccine — 6-K · Jul 30, 2024
- BioNTech/Pfizer COVID-19 Vaccine Gets EU CHMP Recommendation — 6-K · Jun 28, 2024
- BioNTech's Cancer Drug Gets FDA Fast Track — 6-K · Jun 24, 2024
- BioNTech cancer vaccine BNT151 gets FDA green light for Phase 1 trial — 6-K · Jun 17, 2024
- BioNTech SE Presents Promising Phase 2 Data for Kav-cel Combo — 6-K · Jun 3, 2024
- BioNTech Partners with CEPI for Lassa Fever Vaccine — 6-K · May 30, 2024
- BioNTech SE to Present Clinical Trial Data — 6-K · May 21, 2024
- BioNTech SE Holds 2024 Annual General Meeting — 6-K · May 17, 2024
- BioNTech SE Reports Q1 2024 Financial Results — 6-K · May 6, 2024
- BioNTech SE: 3-Year Pancreatic Cancer Trial Data Released — 6-K · Apr 8, 2024
- BioNTech SE Files 6-K Amid NIH Discussions — 6-K · Mar 25, 2024
- BioNTech SE Files 20-F Annual Report for Fiscal Year 2023 — 20-F · Mar 20, 2024
- BioNTech to Present Oncology Pipeline Data at AACR Meeting — 6-K · Mar 11, 2024
- BioNTech SE: Chief Business Officer Sean Marett to Retire — 6-K · Mar 7, 2024
- BioNTech SE Files SC 13D on Autolus Therapeutics Stake — SC 13D · Feb 21, 2024
- Biontech Se SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- BioNTech & Autolus Partner on CAR-T Cell Therapy Commercialization — 6-K · Feb 8, 2024
- ATHOS KG Maintains Significant BioNTech Stake as of Dec 31, 2023 — SC 13G/A · Feb 7, 2024
- BioNTech & DualityBio's BNT325/DB-1305 Gets FDA Fast Track for Ovarian Cancer — 6-K · Jan 31, 2024
- BioNTech & DualityBio Start Pivotal Phase 3 Trial for Breast Cancer Drug BNT323/DB-1303 — 6-K · Jan 22, 2024
- BioNTech Outlines 2024 Strategic Priorities, Targets 10+ Registrational Trials — 6-K · Jan 9, 2024